“Our ability to perform both healthy volunteer trials as well as specialty trials with fullservices will garner efficiencies and drive quality for our partners” said Amy Young, vice president and general manager at DCR. “As research trends continue to involve patient studies earlier in the trial process, the ability to have real-time access to accurate data from a single organization becomes increasingly important.”
Employing software and fully validated systems, the data management services group demonstrates DCR’s ongoing commitment to offer best-in-class development capabilities. DCR has conducted more than 90 early clinical trials in more than 1,000 patients and healthy normal volunteers since 2009, including specialty populations and first-in-human studies. DCR now operates 122beds across two Phase I units in Minneapolis, Minn. and Denver, Colo.
The data management services team will be led by Michael Kreuter, director of DCR, who is located in Denver.
“Data integrity and patient safety are critical in Phase I clinical trial work,” saidKreuter. “We are building on DCR’s solid track record in those areas with a full range of data services necessary for early clinical work.”
Features of the data services group include:
Programmed systems using guidance from CDISC, ICH and other current guides
Client standards, which can be customized and used for future studies
Delivery of final datasets in industry standards including:
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.